dr. abedin on the role of venetoclax plus obinutuzumab in cll
Published 5 years ago • 222 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
0:19
copy of dr. abedin on the role of venetoclax plus obinutuzumab in cll
-
1:56
dr. abedin discusses key updates in cll
-
1:25
dr. abedin discusses differences between acalabrutinib and ibrutinib in cll
-
8:16
venetoclax and obinutuzumab in cll
-
1:03
dr. flinn on toxicities with venetoclax plus obinutuzumab in cll
-
1:02
dr. gerson on venetoclax/obinutuzumab combination in cll
-
0:46
dr. fakhri on tumor lysis syndrome associated with venetoclax/obinutuzumab in cll
-
0:53
dr. abedin on pi3k inhibitors in cll
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
1:07
dr. siddiqi on the cll14 trial results in cll
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
1:25
dr. rogers discusses obinutuzumab, ibrutinib, and venetoclax combination in cll
-
1:24
dr. awan discusses venetoclax in cll
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
1:58
dr. eradat on the captivate trial in cll
-
1:51
dr. barrientos on remaining challenges in cll
-
0:54
dr. davids discusses ongoing research with ibrutinib plus venetoclax in cll
-
6:53
frontline therapy in cll: combination strategies and mrd
-
2:12
dr. tedeschi on ibrutinib for the first-line treatment of older patients with cll